GlassScriptPhysician profile
Victoria Scheibel
NPI 1871985804
$9,685.99
in general payments reported to CMS, 2019-2025
35 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $796 · 2022: $1,252 · 2023: $3,021 · 2024: $2,967 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,561 · Education: $76.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,561.44 |
| Education | $76.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,874.89 | 2021-2025 | |
| Janssen Biotech, INC. | $1,532.57 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $801.56 | 2021-2025 | Xifaxan |
| Pfizer INC. | $381.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.98 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $371.38 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $354.70 | 2022-2025 | Dupixent |
| Celgene Corporation | $312.20 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $312.15 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $302.75 | 2023-2024 | Ibsrela |
| Gilead Sciences, INC. | $264.28 | 2021-2025 | |
| Braintree Laboratories, INC. | $218.24 | 2021-2023 | Sutab |
| Genzyme Corporation | $180.70 | 2023-2025 | |
| Qol Medical, LLC | $130.55 | 2021-2025 | Sucraid |
| Madrigal Pharmaceuticals | $128.58 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $120.29 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $119.11 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $115.80 | 2023-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $114.76 | 2021-2024 | Rebyota |
| Lilly USA, LLC | $101.70 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $98.86 | 2021-2024 | Dificid |
| Celltrion USA INC. | $71.57 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $61.54 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $59.95 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Daiichi Sankyo INC. | $44.89 | 2021-2024 | Injectafer |
| Laborie Medical Technologies Corp. | $37.73 | 2024 | |
| Novo Nordisk INC | $25.84 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $25.84 | 2023 | Zeposia |
| Orphalan INC | $24.15 | 2025 | Cuvrior |
| Amgen INC. | $23.91 | 2025 | Uplizna |
| W. L. Gore & Associates, INC. | $23.46 | 2023 | Gore Cardioform Septal Occluder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.83 | 2023 | Cyltezo |
| Evoke Pharma, INC. | $20.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.11 | 2023 | Givlaari |
| Intra-Sana Laboratories | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Scheibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.